Basic and clinical studies on temafloxacin in urogenital infections

Kazuhiro Hata, Toyohiko Watanabe, Tadasu Takenaka, Satoshi Uno, Toshihide Hayashi, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Katsuyoshi Kondo, Shin Irie, Tetsuzo Kaneshige

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100% (2/2) in acute uncomplicated cystitis and 69.2% (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7%) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases.

Original languageEnglish
Pages (from-to)537-546
Number of pages10
Publication statusPublished - Jan 1 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on temafloxacin in urogenital infections'. Together they form a unique fingerprint.

Cite this